- Home
- MCB vs AVTX Comparison
MCB vs AVTX Comparison
Compare MCB & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MCB | AVTX |
|---|---|---|
| Founded | 1999 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 982.5M |
| IPO Year | 2017 | 2015 |
Fundamental Metrics
Financial Performance| Metric | MCB | AVTX |
|---|---|---|
| Price | $94.04 | $19.59 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $98.67 | $40.57 |
| AVG Volume (30 Days) | 134.4K | ★ 789.3K |
| Earning Date | 04-21-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.13% | N/A |
| EPS Growth | 11.64 | ★ 72.07 |
| EPS | ★ 4.40 | N/A |
| Revenue | $11,053,000.00 | ★ $27,813,137.00 |
| Revenue This Year | $37.22 | N/A |
| Revenue Next Year | $14.75 | N/A |
| P/E Ratio | $21.45 | ★ N/A |
| Revenue Growth | N/A | ★ 2312.27 |
| 52 Week Low | $64.66 | $8.41 |
| 52 Week High | $102.04 | $24.27 |
Technical Indicators
Market Signals| Indicator | MCB | AVTX |
|---|---|---|
| Relative Strength Index (RSI) | 49.26 | 55.81 |
| Support Level | $86.40 | $17.40 |
| Resistance Level | $94.08 | $20.68 |
| Average True Range (ATR) | 2.12 | 1.16 |
| MACD | 0.18 | 0.01 |
| Stochastic Oscillator | 70.98 | 78.22 |
Price Performance
Historical ComparisonAbout MCB Metropolitan Bank Holding Corp.
Metropolitan Bank Holding Corp is a bank holding company. It provides a broad range of business, commercial, and retail banking products and services to small businesses, middle-market enterprises, public entities, and individuals in the New York metropolitan area. The services provided by the company include deposits, trade finance, cash management solutions, savings, electronic banking, cards, and others. The company also provides various lending products such as acquisition loans, construction loans, and lines of credit, for retail, office, hospitality, multifamily, mixed-use, warehouse and distribution, and specialty-use properties. The bank derives its revenue in the form of interest income on loans.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.